v3.25.4
Consolidated Statement of Changes in Equity - USD ($)
$ in Millions
Total
Common stock and additional paid-in capital
Retained earnings
Treasury stock
Accumulated other comprehensive income (loss)
Non-controlling interest
Balance at the beginning of the period at Dec. 31, 2022 $ 14,770 $ 6,700 $ 47,950 $ (33,255) $ (6,673) $ 48
Increase (decrease) in equity            
Net income (loss) (6,979) [1]   (6,995)     16
Other comprehensive income (loss), net of tax (105)       (105) 0
Dividends declared (3,311)   (3,311)      
Stock-based compensation 265 265        
Reacquired stock (33)     (33)    
Dividend to noncontrolling interest (3)         (3)
Issuances pursuant to stock options and benefit plans 264   (165) 429    
Balance at the end of the period at Dec. 31, 2023 4,868 6,965 37,479 (32,859) (6,778) 61
Increase (decrease) in equity            
Net income (loss) 4,188 [1]   4,173     15
Other comprehensive income (loss), net of tax 462       463 (1)
Solventum spin-off (2,167)   (2,751)   584  
Dividends declared (1,982)   (1,982)      
Stock-based compensation 273 273        
Reacquired stock (1,817)     (1,817)    
Dividend to noncontrolling interest (23)         (23)
Issuances pursuant to stock options and benefit plans 92   (122) 214    
Balance at the end of the period at Dec. 31, 2024 3,894 7,238 36,797 (34,462) (5,731) 52
Increase (decrease) in equity            
Net income (loss) 3,262 [1]   3,250     12
Other comprehensive income (loss), net of tax 648       651 (3)
Solventum spin-off (3)   (14)   11  
Dividends declared (1,562)   (1,562)      
Stock-based compensation 211 211        
Reacquired stock (3,249)     (3,249)    
Dividend to noncontrolling interest (16)         (16)
Issuances pursuant to stock options and benefit plans 1,562   (213) 1,775    
Balance at the end of the period at Dec. 31, 2025 $ 4,747 $ 7,449 $ 38,258 $ (35,936) $ (5,069) $ 45
[1] The Consolidated Statements of Cash Flows include the results of continuing and discontinued operations and, therefore, also include cash and cash equivalents associated with Solventum through its April 2024 separation from 3M that were presented in current assets of discontinued operations in the 3M Consolidated Balance Sheet.